Microba Life Sciences Limited

MAP.ASX

Health Care

Microba is a commercial stage company with leading technology for measuring the human gut microbiome.

Market Data

Price

$0.067

-0.0%
Market Cap

$42.0M

P/E Ratio

-100000.0x

EPS

$-0.038

Div. Yield

0.00%

52-Week Change

-0.4%

Latest Earnings

Appendix 4D & FY26 Interim Report

26 February 2026

Revenue
$7.32
-9.0% YoY
NPAT
-$8.73
-5.8% YoY
EPS
$-0.02

Microba Life Sciences reported H1 FY26 revenue of $7.32M, down 9% due to planned legacy product discontinuation, but core testing revenue surged 123% with over 10,000 tests sold. The company completed its strategic transition by discontinuing all legacy products and expects clean revenue growth from Q3, tracking towards regional break-even by end of FY26. Key points: Core test volume up 113% to 10,258 tests sold globally, more than doubling prior period; Microbiome Explorer now represents 55% of total revenue, up from 20% previously; UK adoption outperforming Australia by 33% at equivalent time post launch

Recent Announcements

28 Apr 2026 Supplementary Neutral

Details of Q3 FY26 Quarterly Report, Appendix 4C & Webinar

Microba Life Sciences Limited (ASX: MAP) announced it will release its Q3 FY26 Quarterly Activities Report, Appendix 4C, and Investor Presentation on Thursday, 30 April 2026, with a live Quarterly Investor Webinar hosted by CEO Dr Luke Reid at 11:00am AEST on the same date.

26 Feb 2026 Actual Results Positive

Appendix 4D & FY26 Interim Report

Microba Life Sciences reported H1 FY26 revenue of $7.32M, down 9% due to planned legacy product discontinuation, but core testing revenue surged 123% with over 10,000 tests sold. The company completed its strategic transition by discontinuing all legacy products and expects clean revenue growth from Q3, tracking towards regional break-even by end of FY26. Key points: Core test volume up 113% to 10,258 tests sold globally, more than doubling prior period; Microbiome Explorer now represents 55% of total revenue, up from 20% previously; UK adoption outperforming Australia by 33% at equivalent time post launch

Get real-time alerts for MAP

Receive AI-powered earnings summaries and instant notifications when Microba Life Sciences Limited releases results.

Register Free